SCHEMBL5544299

SCHEMBL5544299

O=[C]CCN1CCN(C(=O)OCc2cccc(Cl)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 6/20 0.47
ATXN2 Q99700 1/20 0.46
ATM Q13315 1/20 0.44
HTR1A P08908 2/20 0.44
HTR7 P34969 2/20 0.44
KCNH2 Q12809 1/20 0.43
HCAR2 Q8TDS4 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
FAAH O00519 1/20 0.43
GRM5 P41594 1/20 0.42
FNTA P49354 1/20 0.42
FNTB P49356 1/20 0.42
PGGT1B P53609 1/20 0.42
LMNA P02545 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547587 0.93 MEN1 (0.47) ENPP2ATXN2ATMHTR1AHTR7
SCHEMBL5542100 0.92 MEN1 (0.46) ENPP2ATXN2ATMHTR1AHTR7
SCHEMBL5537454 0.87 ENPP2 (0.49) ENPP2ATXN2ATMHTR1AHTR7
SCHEMBL5537959 0.85 MEN1 (0.57) ENPP2HTR1AHTR7MEN1KMT2A
SCHEMBL27610405 0.85 MEN1 (0.49) ENPP2ATXN2ATMHTR1AHTR7
SCHEMBL5537253 0.84 MEN1 (0.48) ENPP2ATXN2ATMHTR1AHTR7
SCHEMBL5544309 0.84 ENPP2 (0.47) ENPP2ATXN2ATMHTR1AHTR7
SCHEMBL5541721 0.83 ENPP2 (0.50) ENPP2ATXN2ATMKCNH2HCAR2
SCHEMBL28015689 0.83 HRH2 (0.48) ENPP2ATXN2HTR7MEN1KMT2A
SCHEMBL5547593 0.82 MEN1 (0.47) ENPP2ATXN2ATMHTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ENPP2 2915/4885ATXN2 3603/4885ATM 3644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.